Today: 11 June 2026
Visa stock nudges higher as earnings near and Visa Direct expands crypto cash-outs
23 January 2026
2 mins read

Visa stock nudges higher as earnings near and Visa Direct expands crypto cash-outs

New York, Jan 22, 2026, 17:51 EST — After-hours

  • Visa shares ended the day up 0.3%, holding steady in after-hours trading
  • After a volatile run for card-linked stocks, investors are bracing for Visa’s results due Jan. 29
  • Fresh partnerships in crypto payouts and account-to-account transfers highlight growth avenues beyond traditional card payments

Visa Inc shares ended Thursday up 0.33% at $326.36 and held steady in after-hours trading.

The stock’s modest shift masks a larger story: investors are positioning themselves ahead of next week’s earnings and weighing if the recent drop in payments stocks has bottomed out.

Visa is increasingly moving volume onto rails that don’t resemble the traditional card swipe. That shift is significant as regulators and merchants continue to push for more cost-effective payment routes.

Visa plans to release its fiscal first-quarter earnings on Jan. 29 after markets close, followed by a webcast at 5 p.m. Eastern. The company noted it remains in a “quiet period” leading up to the earnings release. Visa

On Thursday, a crypto-related development emerged. Payments infrastructure company Mercuryo announced a partnership with Visa to broaden “off-ramping”—the process of turning crypto tokens into fiat currency—through Visa Direct, Visa’s platform for real-time money transfers. PR Newswire

Mercuryo CEO Petr Kozyakov said the partnership will simplify converting token balances into cash usable at merchants accepting Visa. Anastasia Serikova, head of Visa Direct in Europe, added the integration aims to make crypto-to-fiat conversion “faster, simpler, and more accessible.” PR Newswire

The day before, Visa was tied to a U.K. initiative aimed at boosting account-to-account payments, which transfer funds directly between bank accounts instead of relying on card networks. Payments company Acquired.com revealed the deal would leverage the U.K.’s Faster Payments system for both recurring and variable payments, while Visa supplies the rules and governance.

Mastercard shares climbed 1% on Thursday, riding the wave of gains in U.S. stocks, while Visa held pace with other major financial players.

The macro and political landscape remains in focus. On Thursday, Reuters reported that Bank of America and Citigroup are considering new credit cards with interest rates around 10%, amid discussions over President Donald Trump’s proposal for a nationwide rate cap. This debate continues to spotlight how profits are distributed across the credit-card stack.

Two sessions ago, Reuters noted a drop in U.S. bank stocks as investors held their breath on whether the administration’s deadline for the proposed cap would have an impact, highlighting just how swiftly policy moves can ripple through payments and bank valuations.

Visa’s annual meeting is set for Jan. 27, as noted in its proxy filing.

The biggest threat for Visa bulls is straightforward. Should consumer spending dip, travel falter, or lawmakers make headway on routing or fee changes, Visa could still slide despite strong earnings.

Traders will be watching to see if Thursday’s late-session stability carries over into Friday. Looking ahead, all eyes turn to Jan. 27’s annual meeting and the Jan. 29 earnings report and call, when Visa breaks its silence following the quiet period.

Stock Market Today

  • Ideaya Biosciences Stock Drops 10% Amid $300M Fundraising Despite Bullish Outlook
    June 10, 2026, 10:30 PM EDT. Shares of Ideaya Biosciences ($IDYA) fell 10% to around $27 following the announcement of a $300 million stock offering priced at $27 per share, diluting existing shareholder value. The biotech firm had surged 13% earlier due to promising oncology trial results presented at ASCO. Analysts from Citizens reaffirmed a Market Outperform rating and a $45 target, citing robust pipeline developments and collaborations, including a deal with Roche on a novel oncology drug combination. Positive clinical data showed a 37% response rate in uveal melanoma, substantially outperforming standard care. The cash raise aims to advance multiple cancer trials, ensuring a solid financial runway despite near-term stock pressure from dilution.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud
Previous Story

Autodesk layoffs: AutoCAD maker to cut 1,000 jobs as it shifts spending to AI and cloud

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week
Next Story

AbbVie stock rises as Wall Street rallies; traders eye Feb. 4 earnings and the Fed next week

Go toTop